China's drug regulator approved Honz Pharmaceutical's (SHE:300086) clinical trial for a pediatric indication for its Ceftazidime Tazobactam Sodium injection, according to a Tuesday filing with the Shenzhen bourse.
The drug treats moderate to severe infections caused by beta-lactamase-producing bacteria.
Jahen Household Products (SHE:300955) and its subsidiaries will seek a 980 million yuan comprehensive credit line, according to a Tuesday filing with the Shenzhen bourse.The manufacturer of chemical products and plastic containers will provide a guarantee of 830 million yuan for its wholly owned subsidiaries.
Xiaomi (HKG:1810) recorded a decline in attributable profit for the first quarter of 2026 to 4.72 billion yuan from 10.9 billion yuan a year prior, according to a Tuesday filing with the Hong Kong bourse.Earnings per share were 0.18 yuan in the period, down from 0.42 yuan in the previous fiscal year.The tech giant's revenue slipped 11% to 99.1 billion yuan from 111.3 billion yuan in the year-ago period.
Jiangsu Zongyi (SHA:600770) controlling shareholder Nantong Zongyi Investment plans to increase its shareholding in the company by between 50 million yuan and 100 million yuan, according to a Tuesday filing with the Shanghai bourse.The shareholder will boost its holdings through centralized bidding on the Shanghai Stock Exchange system within one year until May 25, 2027.